Elixirgen Therapeutics Granted FDA Orphan Drug Designation For EXG-34217 For Treatment Of Telomere Biology Disorders
The FDA recently granted EXG-34217 Rare Pediatric Disease Designation (RPDD) and Regenerative Medicine Advanced Therapy (RMAT) Designation .
Pharming Technologies B.V. Increases Its Ownership In Abliva AB (Publ) To 92.70 Percent
This press release is not an offer, whether directly or indirectly, in Australia, Canada, Hong Kong, Japan, New Zealand or South Africa or in any oth ...